CSIMarket
 


Vir Biotechnology Inc   (VIR)
Other Ticker:  
 

Vir Biotechnology Inc 's Working Capital Ratio

VIR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




VIR Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 31.87 % 227.25 % 94.51 % 244.47 % 203.55 %
Y / Y Current Assets Change 126.35 % 165.37 % 158.54 % 102.34 % 25.51 %
Working Capital Ratio MRQ 7.83 4.79 3.66 4.58 4.56
Overall Ranking # # # # #
Seq. Current Liabilities Change -35.5 % -31.96 % 105.82 % 46 % 60.06 %
Seq. Current Assets Change 5.48 % -10.88 % 64.29 % 46.56 % 23.66 %



Working Capital Ratio third quarter 2022 Comment
Vir Biotechnology Inc 's Current Assets grew by 5.48 % in the III. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Vir Biotechnology Inc 's Working Capital Ratio to 7.83, above Vir Biotechnology Inc average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry Vir Biotechnology Inc booked the highest Working Capital Ratio than Vir Biotechnology Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is VIR most successful ?
Working Capital Ratio VIR on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Vir Biotechnology Inc 's Current Liabilities $ 308 Millions Visit VIR's Balance sheet
Vir Biotechnology Inc 's Current Assets $ 2,414 Millions Visit VIR's Balance sheet
Source of VIR's Sales Visit VIR's Sales by Geography


Cumulative Vir Biotechnology Inc 's Working Capital Ratio

VIR's Working Capital Ratio for the trailling 12 Months

VIR Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 31.87 % 227.25 % 94.51 % 244.47 % 203.55 %
Y / Y Current Assets TTM Growth 126.35 % 165.37 % 158.54 % 102.34 % 25.51 %
Working Capital Ratio TTM 4.83 4.26 4.26 4.14 4.4
Total Ranking TTM # 377 # 1192 # 541 # 1348 # 1045
Seq. Current Liabilities TTM Growth -35.5 % -31.96 % 105.82 % 46 % 60.06 %
Seq. Current Assets TTM Growth 5.48 % -10.88 % 64.29 % 46.56 % 23.66 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis VIR Current Assets average more than doubled by 126.35 % in III. Quarter year on year, faster than Current Liabilities, this led to increase in in Vir Biotechnology Inc 's Working Capital Ratio to 4.83, Working Capital Ratio remained below VIR average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 64 other companies have achieved higher Working Capital Ratio than Vir Biotechnology Inc . While overall ranking remained unchanged compare to previous quarter at no. 377.

Explain Working Capital Ratio
Where is VIR most successful ?
Working Capital Ratio VIR on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 65
Healthcare Sector # 240
Within the Market # 377


TTM Working Capital Ratio Statistics
High Average Low
8.97 5.92 4.14
(Dec 31 2020)   (Dec 31 2021)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Celldex Therapeutics inc   20.54 $ 334.599  Millions$ 16.287  Millions
Quince Therapeutics Inc   19.87 $ 98.276  Millions$ 4.945  Millions
Vor Biopharma Inc   19.43 $ 142.729  Millions$ 7.345  Millions
Fusion Pharmaceuticals Inc   18.02 $ 215.846  Millions$ 11.981  Millions
Icosavax Inc   17.55 $ 228.732  Millions$ 13.033  Millions
Organovo Holdings Inc   17.54 $ 24.357  Millions$ 1.389  Millions
4d Molecular Therapeutics Inc   17.14 $ 232.478  Millions$ 13.564  Millions
Tarsus Pharmaceuticals Inc   16.40 $ 234.078  Millions$ 14.273  Millions
Vaxcyte Inc   16.35 $ 369.759  Millions$ 22.614  Millions
Replimune Group Inc   16.12 $ 379.390  Millions$ 23.537  Millions
Cardiff Oncology inc   15.82 $ 119.755  Millions$ 7.571  Millions
Anavex Life Sciences Corp   15.63 $ 152.705  Millions$ 9.770  Millions
Kymera Therapeutics Inc   15.57 $ 494.022  Millions$ 31.729  Millions
Relay Therapeutics Inc   15.22 $ 1,087.297  Millions$ 71.427  Millions
Candel Therapeutics Inc   14.52 $ 79.070  Millions$ 5.446  Millions
Entera Bio Ltd   14.28 $ 15.190  Millions$ 1.064  Millions
Krystal Biotech Inc   14.18 $ 397.578  Millions$ 28.032  Millions
Tracon Pharmaceuticals inc   14.05 $ 18.020  Millions$ 1.283  Millions
Monte Rosa Therapeutics Inc   13.55 $ 295.235  Millions$ 21.790  Millions
Century Therapeutics inc   13.44 $ 361.641  Millions$ 26.907  Millions
Immunovant Inc   13.41 $ 426.091  Millions$ 31.784  Millions
Talis Biomedical Corporation  13.22 $ 150.377  Millions$ 11.378  Millions
Allovir Inc   13.13 $ 272.042  Millions$ 20.719  Millions
Crispr Therapeutics Ag  12.81 $ 1,932.703  Millions$ 150.870  Millions
Compass Therapeutics Inc   12.80 $ 122.554  Millions$ 9.578  Millions
Rubius Therapeutics Inc   12.71 $ 110.823  Millions$ 8.717  Millions
Chase Corporation  12.42 $ 438.898  Millions$ 35.328  Millions
Ginkgo Bioworks Holdings Inc   11.71 $ 1,462.003  Millions$ 124.818  Millions
Allogene Therapeutics Inc   11.64 $ 569.061  Millions$ 48.872  Millions
Aura Biosciences Inc   11.63 $ 115.908  Millions$ 9.964  Millions

Date modified: 2022-11-06T04:16:49+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FDBL's Profile

Stock Price

FDBL's Financials

Business Description

Fundamentals

Charts & Quotes

FDBL's News

Suppliers

FDBL's Competitors

Customers & Markets

Economic Indicators

FDBL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071